skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands

Journal Article · · European Journal of Medicinal Chemistry
ORCiD logo [1];  [1];  [1];  [1];  [1];  [2];  [2];  [3];  [2];  [4]
  1. Purdue Univ., West Lafayette, IN (United States)
  2. Georgia State Univ., Atlanta, GA (United States)
  3. National Center for Global Health & Medicine Research Inst., Tokyo (Japan)
  4. National Center for Global Health & Medicine Research Inst., Tokyo (Japan); Kumamoto University Graduate School of Medical and Pharmaceutical Sciences (Japan); National Inst. of Health (NIH), Bethesda, MD (United States)
+ Show Author Affiliations

We describe the design, synthesis, and biological evaluation of a series of novel HIV-1 protease inhibitors with carboxamide derivatives as the P2 ligands. We have specifically designed aminothiochromane and aminotetrahydronaphthalene-based carboxamide ligands to promote hydrogen bonding and van der Waals interactions in the active site of HIV-1 protease. Inhibitors 4e and 4j have shown potent enzyme inhibitory and antiviral activity. High resolution X-ray crystal structures of 4d- and 4k-bound HIV-1 protease revealed molecular insights into the ligand-binding site interactions.

Research Organization:
Argonne National Laboratory (ANL), Argonne, IL (United States)
Sponsoring Organization:
USDOE Office of Science (SC); National Inst. of Health
Grant/Contract Number:
GM53386; GM62920
OSTI ID:
1482242
Journal Information:
European Journal of Medicinal Chemistry, Vol. 160, Issue C; ISSN 0223-5234
Publisher:
ElsevierCopyright Statement
Country of Publication:
United States
Language:
ENGLISH
Citation Metrics:
Cited by: 2 works
Citation information provided by
Web of Science

References (53)

Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS journal January 2016
Demonstration of Sustained Drug-Resistant Human Immunodeficiency Virus Type 1 Lineages Circulating among Treatment-Naive Individuals journal January 2009
Thirty Years of HIV and AIDS: Future Challenges and Opportunities journal June 2011
Prevention of HIV-1 Infection with Early Antiretroviral Therapy journal August 2011
Improved survival in HIV-infected persons: consequences and perspectives journal July 2007
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study journal August 2010
Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV journal December 2007
Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro journal September 2003
TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates journal May 2005
Design of HIV Protease Inhibitors Targeting Protein Backbone: An Effective Strategy for Combating Drug Resistance journal January 2008
Enhancing Protein Backbone Binding-A Fruitful Concept for Combating Drug-Resistant HIV journal January 2012
High Resolution Crystal Structures of HIV-1 Protease with a Potent Non-peptide Inhibitor (UIC-94017) Active Against Multi-drug-resistant Clinical Strains journal April 2004
Ultra-high Resolution Crystal Structure of HIV-1 Protease Mutant Reveals Two Binding Sites for Clinical Inhibitor TMC114 journal October 2006
Design and synthesis of potent HIV-1 protease inhibitors with ( S )-tetrahydrofuran-tertiary amine-acetamide as P2−ligand: Structure−activity studies and biological evaluation journal September 2017
Disubstituted Bis-THF Moieties as New P2 Ligands in Nonpeptidal HIV-1 Protease Inhibitors (II) journal April 2015
HIV-1 protease inhibitors with a tertiary alcohol containing transition-state mimic and various P2 and P1′ substituents journal January 2011
Variations of the P2 group in HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold journal January 2006
Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors journal March 2012
Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands journal May 2015
Discovery of MK-8718, an HIV Protease Inhibitor Containing a Novel Morpholine Aspartate Binding Group journal May 2016
Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease Inhibitors journal November 2017
Structure-Based Design of Novel HIV-1 Protease Inhibitors To Combat Drug Resistance journal August 2006
Probing Multidrug-Resistance and Protein-Ligand Interactions with Oxatricyclic Designed Ligands in HIV-1 Protease Inhibitors journal September 2010
Design of Highly Potent, Dual-Acting and Central-Nervous-System-Penetrating HIV-1 Protease Inhibitors with Excellent Potency against Multidrug-Resistant HIV-1 Variants journal March 2018
A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency journal October 2017
Bis-Tetrahydrofuran: a Privileged Ligand for Darunavir and a New Generation of HIV Protease Inhibitors That Combat Drug Resistance journal September 2006
Design and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1–P2 ligands journal January 2014
Structure-Based Design:  Synthesis and Biological Evaluation of a Series of Novel Cycloamide-Derived HIV-1 Protease Inhibitors journal May 2005
Design of novel HIV-1 protease inhibitors incorporating isophthalamide-derived P2-P3 ligands: Synthesis, biological evaluation and X-ray structural studies of inhibitor-HIV-1 protease complex journal October 2017
Countering Cooperative Effects in Protease Inhibitors Using Constrained β-Strand-Mimicking Templates in Focused Combinatorial Libraries journal February 2004
Viracept (Nelfinavir Mesylate, AG1343):  A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease journal November 1997
Syntheses of 3-Cyano-3-methyl-4-thiochromanone and 3-Carbomethoxy-3-methyl-4-thiochromanone journal January 1966
One-Pot Asymmetric Synthesis of Either Diastereomer of tert-Butanesulfinyl-protected Amines from Ketones journal December 2006
Reversal of Diastereofacial Selectivity in Hydride Reductions of N - tert -Butanesulfinyl Imines journal September 2006
Palladium-Catalyzed Carbonylation Reactions of Aryl Bromides at Atmospheric Pressure: A General System Based on Xantphos journal September 2008
Asymmetric Catalysis by Architectural and Functional Molecular Engineering: Practical Chemo- and Stereoselective Hydrogenation of Ketones journal January 2001
Asymmetric Hydrogenation of α-Chloro Aromatic Ketones Catalyzed by η6-Arene/TsDPEN−Ruthenium(II) Complexes journal December 2006
A simple, continuous fluorometric assay for HIV protease journal December 1990
Cyclic sulfolanes as novel and high-affinity P2 ligands for HIV-1 protease inhibitors journal April 1993
The Development of Cyclic Sulfolanes as Novel and High-Affinity P2 Ligands for HIV-1 Protease Inhibitors journal April 1994
Structural implications of drug-resistant mutants of HIV-1 protease: High-resolution crystal structures of the mutant protease/substrate analogue complexes journal January 2001
[20] Processing of X-ray diffraction data collected in oscillation mode book January 1997
Phaser crystallographic software journal July 2007
Overview of the CCP 4 suite and current developments journal March 2011
The CCP4 suite programs for protein crystallography journal September 1994
A graphical user interface to the CCP 4 program suite journal June 2003
Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters: HIV protease mutants altering hydrophobic clusters journal August 2010
A short history of SHELX journal December 2007
[16] SHELXL: High-resolution refinement book January 1997
PRODRG : a tool for high-throughput crystallography of protein–ligand complexes journal July 2004
Features and development of Coot journal March 2010
Coot model-building tools for molecular graphics journal November 2004
The Protein Data Bank journal January 2000

Similar Records

Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure–Activity Studies and Biological and X-ray Structural Studies
Journal Article · Wed Oct 24 00:00:00 EDT 2018 · Journal of Medicinal Chemistry · OSTI ID:1482242
+7 more
Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants
Journal Article · Tue Apr 18 00:00:00 EDT 2017 · Journal of Medicinal Chemistry · OSTI ID:1482242
+10 more
Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure–Activity Studies, Biological and X-ray Structural Analysis
Journal Article · Tue May 15 00:00:00 EDT 2018 · Journal of Medicinal Chemistry · OSTI ID:1482242
+9 more

Related Subjects

59 BASIC BIOLOGICAL SCIENCES
HIV-1 protease inhibitors
P2 ligand
drug resistance
design and synthesis
X-ray crystal structure